Proliferative lesions of oviduct and uterus in CD-1 mice exposed prenatally to tamoxifen

Carcinogenesis

Volumn 18, Issue 10, 1997, Pages 2009-2014

  Diwan, Bhalchandra A ^a   Anderson, Lucy M ^b   Ward, Jerrold M ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

ADENOMA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ENDOMETRIUM HYPERPLASIA; FEMALE; GRANULOSA CELL TUMOR; HYPERPLASIA; LEIOMYOMA; LEIOMYOSARCOMA; MOUSE; NONHUMAN; OVIDUCT; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; UTERUS; UTERUS DISEASE;

ANIMALS; ANTICARCINOGENIC AGENTS; ENDOMETRIAL HYPERPLASIA; ESTROGEN ANTAGONISTS; FALLOPIAN TUBES; FEMALE; HYPERPLASIA; MALE; MICE; POLYPS; PRECANCEROUS CONDITIONS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TAMOXIFEN; UTERINE NEOPLASMS; UTERUS;

EID: 0031425984     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/18.10.2009     Document Type: Article

References (23)

1. Fisher, B., Constantino, J., Redmond, C.K., Fisher, E.R., Wickerham, D.L. and Cronin, W.M. (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor positive tumors. N. Engl. J. Med., 320, 479-484.
2. Early Breast Cancer Trialist's Collaborative Group. (1992) Systematic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339, 1-15 and 71-85.
3. Jordan, V.C. (1995) Tamoxifen for breast cancer prevention. Proc. Soc. Exp. Biol. Med., 208, 144-149.
4. King, C.M. (1995) Tamoxifen and the induction of cancer. Carcinogenesis, 16, 1449-1454.
5. Van Leeuwen, F.E., Benraadt, T.J., Coebergh, J.W.W., Kiemeney, L.A.L.M., Gimbrere, C.H.F., Otter, R., Schouten, L.J., Damhuis, R.A.M., Bontenbal, M. and Diepenhorst, F.W. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancer, 343, 448-452.
6. Silva, E.G., Tornos, C.S. and Follen-Mitchell, M. (1994) Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effect of tamoxifen. Int. J. Gynecol. Pathol., 13, 248-258.
7. Rutqvist, L.E., Johansson, H., Signomklao, T., Johansson, U., Fornader, T. and Wilking, N. (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl Cancer Inst., 87, 645-650.
8. White, N.H.I., de Matteis, F.D., Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer, A. and Philips, D.H. (1992) Genotoxic potential of tamoxifen and its analogues in female Fisher F344/n rats, DBA/2 and C57BL/ 6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
9. Hemminki, K., Rajaniemi, H., Lindahl, B. and Moberger, B. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 56, 4374-4377.
10. Hemminki, K., Widlak, P. and Hou, S.-M. (1995) DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis, 16, 1661-1664.
11. Hemminki, K., Rajaniemi, H., Koskinen, M. and Hansson, J. (1997) Tamoxifen-induced DNA adducts in leukocytes of breast cancer patients. Carcinogenesis, 18, 9-13.
12. Marselos, M. and Tomatis, L. (1992) Diethylstilbestrol: I, pharmacology, toxicology and carcinogenicity in humans. Eur. J. Cancer, 28, 1182-1189.
13. Fromson, J.M., Pearson, S. and Bramah (neé Meek), S. (1973) The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. Xenobiotica, 3, 693-709.
14. Mikkelson, T.J., Kroboth, P.D., Cameron, W.J., Dittert, L.W., Chungi, V. and Manberg, P.J. (1986) Single dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil. Steril., 46, 392-396.
15. Newbold, R., Bullock, B., Jefferson, W. and Padilla-Burgos, E. (1996) Effects of developmental exposure of mice to tamoxifen. Proc. Amer. Assoc. Cancer Res., 37, 109.
16. Spontaneous neoplastic lesions in the Crl:CD-1 BR mouse. Charles River Laboratories Publication. 1995.
17. Johnson, L.D. (1987) Lesions of the female genital system caused by diethylstilbestrol in humans, subhuman primates, and mice. In Jones, T.C., Mohr, U. and Hunt, R.D. (eds) Genital System. Monographs on Pathology of Laboratory Animals. Springer Verlag, New York, pp. 84-109.
18. Nagaoka, T., Takeuchi, M., Onodera, H., Mitsumori, K., Lu, J. and Maekawa, A. (1994) Sequential observation of spontaneous endometrial adenocarcinoma development in Donryu rats. Toxicol. Pathol., 22, 261-269.
19. Tucker, M.J., Adam, H.K. and Patterson, J.S. (1984) Tamoxifen. In Laurence, D.R., McLean, A.E.M. and Weatherall, M. (eds) Safety Testing of New Drugs. Academic Press, London, pp. 125-161.
20. Martin, E.A., Carthew, P., White, I.N.H. and Smith, L.L. (1996) A lifetime feeding study of tamoxifen in three strains of mice. The Toxicologist, 30, 201.
21. Carthew, P., Edwards, R.E., Nolan, B.M., Martin, E.A. and Smith, L.L. (1996) Tamoxifen associated uterine pathology in rodents: relevance to women. Carcinogenesis, 17, 1577-1582.
22. Newbold, R.R. (1995) Cellular and molecular effects of developmental exposure to diethylstilbestrol: Implications for other environmental estrogens. Environ. Health Perspect., 103, 83-87.
23. Williams, G.M., Iatropoulos, M.J., Djordjevic, M.V. and Kaltenberg, O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.